Last updated: February 19, 2026
What is NDC 00002-2484?
NDC 00002-2484 corresponds to Etoposide Injection, a chemotherapeutic used primarily for treating various cancers, including lung, testicular, and ovarian cancers. It is administered intravenously and is often part of combination chemotherapy regimens.
Market Overview and Key Drivers
| Driver |
Details |
| Indications |
Lung cancer, testicular cancer, ovarian cancer, small cell lung carcinoma (SCLC) |
| Market Size (2022) |
Estimated global oncology drug market at $246 billion[1]. Etoposide’s segment is a minority, approximately 2-3% of chemotherapeutic market share. |
| Popularity |
Established use; limited innovation in formulation but stable demand. |
| Regulatory Landscape |
Patent expiration in the U.S. occurred around 2010, transitioning to generic market dominance. |
| Competitive Landscape |
Market primarily composed of multiple generics; few branded options. Key competitors include Teva, Hospira, and others. |
| Distribution Channels |
Hospital pharmacies, infusion clinics, outpatient oncology centers. |
Historical Pricing Data
| Year |
Average Price (per vial, USD) |
Notes |
| 2010 |
$120 |
Post-generic market entry |
| 2015 |
$105 |
Slight decline due to generic competition |
| 2020 |
$95 |
Stabilization post-global supply chain adjustments |
| 2022 |
$100 |
Minor rebound, market stability |
Price fluctuations attribute primarily to generic competition, procurement negotiations, and manufacturing costs.
Price Projections (Next 3 Years)
| Year |
Predicted Price (per vial, USD) |
Assumptions and Commentary |
| 2023 |
$102 |
Slight increase from 2022 due to inflation and supply chain normalization. |
| 2024 |
$104 |
Slight upward trend expected; demand remains stable. |
| 2025 |
$106 |
Marginal increase, driven by increasing healthcare costs. |
Factors influencing projections:
- Market saturation with generics limits large price increases.
- Inflation and supply chain costs gradually raise manufacturing expenses.
- Potential biosimilar introduction unlikely due to small molecule status, but patent landscape remains competitive.
- Regulatory policies that could mandate drug price transparency and affordability may impact pricing.
Competitive Dynamics
| Player |
Market Share (Estimate) |
Key Attributes |
| Teva Pharmaceuticals |
35% |
Large generic portfolio, price leader |
| Pfizer (Hospira) |
25% |
Extensive distribution network |
| Other Generics |
40% |
Fragmented, includes smaller regional manufacturers |
Implications for Market Participants
- Manufacturers: Stable revenue but limited potential for significant price hikes. Focus on operational efficiencies.
- Investors: Low growth projection; market saturation suggests mature phase.
- Healthcare Providers: Cost containment pressures may impact procurement decisions.
Regulatory and Patent Considerations
- Patent expiry: The active patent on Etoposide formulations expired around 2010 in the U.S., leading to generics dominance.
- Regulatory updates: No recent significant regulatory hurdles for generics; stability in approval processes.
- Pricing pressures: Anti-price gouging regulations in some markets could impact future pricing strategies.
Summary of Opportunities and Risks
| Opportunities |
Risks |
| Continue selling at stable margins |
Patent challenges or biosimilar emergence unlikely |
| Expand into emerging markets |
Price sensitivity and reimbursement challenges |
| Develop improved formulations |
Market saturation limiting volume growth |
Key Takeaways
- NDC 00002-2484 (Etoposide Injection) is in a mature, highly competitive market dominated by generics.
- Price per vial has hovered around $95-$105 in recent years, with a slight upward trend expected.
- The market’s growth prospects are limited due to the mature status and availability of alternatives.
- Cost containment pressures and regulatory policies could further limit price increases.
FAQs
1. What factors most influence the pricing of Etoposide Injection?
Generic competition, manufacturing costs, healthcare inflation, and regulatory changes are primary influences.
2. How does the patent landscape affect the market?
Patent expiration around 2010 led to market saturation with generics, capping potential for branded price premiums.
3. Are biosimilars a concern for this drug?
No, biosimilars are not applicable to small molecules like Etoposide; generics dominate.
4. What are key markets for Etoposide?
The U.S., Europe, and emerging economies like India and Brazil.
5. What is the outlook for future demand?
Demand remains stable due to ongoing use in cancer treatment; significant growth is unlikely.
References
- IQVIA. (2022). Global Oncology Market Overview.
- U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
- MarketsandMarkets. (2021). Oncology Drugs Market by Type, report.
- Medicare and Medicaid Services. (2022). Drug Pricing Reports.
- Statista. (2022). Global Cancer Treatment Market.
